entertainment -WSS

entertainment

author：hotspot 2025-09-28 21:58:44 - browse：1

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

LONDON — A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, its developers said Monday, as the competition in the broader obesity medicine field pushes ahead.

The drug, survodutide, is being developed by the privately held German firm Boehringer Ingelheim and the Danish biotech Zealand Pharma. Zealand’s share price has doubled over the past year over the potential of the drug, and on Monday morning, shares jumped another 25%.

In the study, 83% of patients with a condition called MASH and who were treated with survodutide saw significant improvements in their disease compared to 18% of those who received placebo. The study met its primary endpoint of improvements in MASH after 48 weeks without the worsening of fibrosis, a scarring of the liver, the companies said. Secondary endpoints were also met, including an improvement in fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Readout Newsletter: Merck, Vertex, and Viking updates

leisure time

WSS

Think you might have Covid

Eli Lilly, Pfizer, and others want in on the online prescription market

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Biotech venture capitalists face new demands from investors

States should stop sabotaging methadone treatment reform

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

focus

entertainment

entertainment

At least 13 dead in Texas as scorching temps continue

The Readout: Lenmeldy, GLP

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

At least 13 dead in Texas as scorching temps continue

Research misconduct: Proposed new rules face resistance

Apple is now the first public company to be valued at $3 trillion

Francis Collins on trust in science and how Covid communications failed

Peter Hotez and the public health issue of online harassment

Will generative AI in health care meet the fate of IBM's Dr. Watson?

focus

Eliminate the waiting period for sterilization covered by Medicaid

Steward Health Care has deal to sell doctor network to UnitedHealth

Patient advocates debate FDA's accelerated approval process

FDA's naming rule on biosimilars has undermined competition

Eliminate the waiting period for sterilization covered by Medicaid

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

hotspot

hotspot

leisure time

focus